Microbes that reside peaceably in the nasal passageways and on the skin can be harnessed for taking drugs to target cells.

Raanana, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm in the development stage, has filed a divisional patent application in Israel for its Trap & Target (NYSE:TGT) (T&T) platform technology.

and the Trap and Target (T&T™) system, which is designed for effective nasal drug delivery. The C&C technology is developed as a nasal spray to protect against viruses and allergens, while T&T ...

A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...

The filing represents Polyrizon's ongoing efforts to protect its intellectual property and strengthens the company's position in the field of advanced nasal drug delivery. The T&T platform boasts ...

Dr. Chen is developing a new delivery system which is designed to help cancer drugs cross the blood-brain barrier.

Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a ...

Researchers at University of the Pacific in Stockton have developed a long-acting opioid overdose-reversal drug-delivery ...

A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, potentially improving survival and expanding treatment options. A novel approach ...

Polyrizon (PLRZ) announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target platform ...

The platform leverages the nasal cavity's rich vascularization for both local and systemic drug delivery, which could be beneficial for treating respiratory conditions, central nervous system ...